Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor

Journal of Controlled Release

Volumn 192, Issue , 2014, Pages 29-39

  Valetti, Sabrina ^a,b,c   Maione, Federica ^d   Mura, Simona ^a,b   Stella, Barbara ^c   Desmaële, Didier ^a,b   Noiray, Magali ^a,b   Vergnaud, Juliette ^a,b   Vauthier, Christine ^a,b   Cattel, Luigi ^c   Giraudo, Enrico ^c,d   Couvreur, Patrick ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIV PARIS SUD   (France)

^c UNIVERSITY OF TURIN   (Italy)

^d CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Gemcitabine; Pancreatic cancer; Squalene nanoparticles; Targeted nanoparticles; Tumor targeting peptide

Indexed keywords

ALIPHATIC COMPOUNDS; CHEMOTHERAPY; DISEASES; DISPLAY DEVICES; MEDICAL NANOTECHNOLOGY; PEPTIDES; PHAGE DISPLAY; TUMORS;

FUNCTIONALIZATIONS; GEMCITABINE; INTRAVENOUS INJECTIONS; MONODISPERSE NANOPARTICLES; PANCREATIC CANCERS; PEPTIDE-FUNCTIONALIZED NANOPARTICLES; TARGETED NANOPARTICLE; TUMOR TARGETING PEPTIDES;

NANOPARTICLES;

CKAAKN PEPTIDE; GEMCITABINE; NANOPARTICLE; PEPTIDE; SQUALENE; UNCLASSIFIED DRUG; WNT2 PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG CARRIER; PRODRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; IN VIVO STUDY; LIGAND BINDING; MOUSE; NANOMEDICINE; NEOPLASM; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; PERICYTE; PHAGE DISPLAY; PRECIPITATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; SQUALENOYLATION; TUMOR MICROENVIRONMENT; VASCULARIZATION; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; MALE; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MICE, INBRED C57BL; NANOPARTICLES; PANCREATIC NEOPLASMS; PEPTIDES; PRODRUGS; SQUALENE;

EID: 84904554609     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.06.039     Document Type: Article

References (56)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J. Clin. 60 2010 277 300
2. P.E. Oberstein, and M.W. Saif First-line treatment for advanced pancreatic cancer Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011 JOP 12 2011 96 100
3. V. Heinemann, S. Boeck, A. Hinke, R. Labianca, and C. Louvet Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 2008 82
4. A. Sultana, C.T. Smith, D. Cunningham, N. Starling, J.P. Neoptolemos, and P. Ghaneh Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer J. Clin. Oncol. 25 2007 2607 2615 (Pubitemid 47041235)
5. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, S. Gallinger, H.J. Au, P. Murawa, D. Walde, R.A. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, M. Ptasynski, and W. Parulekar Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 25 2007 1960 1966 (Pubitemid 46972777)
6. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2013/ 021660Orig1s037ltr.pdf (in)
7. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, T. Seay, S.A. Tjulandin, W.W. Ma, M.N. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R.K. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Van Cutsem, X.Y. Wei, J. Iglesias, and M.F. Renschler Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N. Engl. J. Med. 369 2013 1691 1703
8. L. Bildstein, C. Dubernet, V. Marsaud, H. Chacun, V. Nicolas, C. Gueutin, A. Sarasin, H. Benech, S. Lepetre-Mouelhi, D. Desmaele, and P. Couvreur Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway J. Control. Release 147 2010 163 170
9. K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M.A. Goldgraben, M.E. Caldwell, D. Allard, K.K. Frese, G. Denicola, C. Feig, C. Combs, S.P. Winter, H. Ireland-Zecchini, S. Reichelt, W.J. Howat, A. Chang, M. Dhara, L. Wang, F. Ruckert, R. Grutzmann, C. Pilarsky, K. Izeradjene, S.R. Hingorani, P. Huang, S.E. Davies, W. Plunkett, M. Egorin, R.H. Hruban, N. Whitebread, K. McGovern, J. Adams, C. Iacobuzio-Donahue, J. Griffiths, and D.A. Tuveson Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
10. Y. Takakura, R.I. Mahato, and M. Hashida Extravasation of macromolecules Adv. Drug Deliv. Rev. 34 1998 93 108 (Pubitemid 28464480)
11. D.E. Owens III, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102 (Pubitemid 41773257)
12. M. Hidalgo Pancreatic cancer N. Engl. J. Med. 362 2010 1605 1617
13. J. Nicolas, S. Mura, D. Brambilla, N. Mackiewicz, and P. Couvreur Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery Chem. Soc. Rev. 42 2013 1147 1235
14. S. Valetti, S. Mura, B. Stella, and P. Couvreur Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice J. Nanobiotechnology 11 2013 S6
15. J.W. Nichols, and Y.H. Bae Odyssey of a cancer nanoparticle: from injection site to site of action Nano Today 7 2012 606 618
16. R.A. Kudgus, A. Szabolcs, J.A. Khan, C.A. Walden, J.M. Reid, J.D. Robertson, R. Bhattacharya, and P. Mukherjee Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics PLoS ONE 8 2013 e57522
17. S. Ji, J. Xu, B. Zhang, W. Yao, W. Xu, W. Wu, Y. Xu, H. Wang, Q. Ni, H. Hou, and X. Yu RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy Cancer Biol. Ther. 13 2012 206 215
18. E.R. Camp, C. Wang, E.C. Little, P.M. Watson, K.F. Pirollo, A. Rait, D.J. Cole, E.H. Chang, and D.K. Watson Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy Cancer Gene Ther. 20 2013 222 228
19. J. Xu, F. Gattacceca, and M. Amiji Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice Mol. Pharm. 10 2013 2031 2044
20. J.A. Joyce, P. Laakkonen, M. Bernasconi, G. Bergers, E. Ruoslahti, and D. Hanahan Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis Cancer Cell 4 2003 393 403 (Pubitemid 37491100)
21. L.H. Reddy, and P. Couvreur Squalene: a natural triterpene for use in disease management and therapy Adv. Drug Deliv. Rev. 61 2009 1412 1426
22. P. Couvreur, B. Stella, L.H. Reddy, H. Hillaireau, C. Dubernet, D. Desmaele, S. Lepetre-Mouelhi, F. Rocco, N. Dereuddre-Bosquet, P. Clayette, V. Rosilio, V. Marsaud, J.M. Renoir, and L. Cattel Squalenoyl nanomedicines as potential therapeutics Nano Lett. 6 2006 2544 2548 (Pubitemid 46076946)
23. D. Willner, P.A. Trail, S.J. Hofstead, H.D. King, S.J. Lasch, G.R. Braslawsky, R.S. Greenfield, T. Kaneko, and R.A. Firestone (6-Maleimidocaproyl) hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin Bioconjug. Chem. 4 1993 521 527 (Pubitemid 2018209)
24. H. Fessi, F. Puisieux, J.P. Devissaguet, N. Ammoury, and S. Benita Nanocapsule formation by interfacial polymer deposition following solvent displacement Int. J. Pharm. 55 1989 R1 R4
25. I. Bertholon, C. Vauthier, and D. Labarre Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide Pharm. Res. 23 2006 1313 1323 (Pubitemid 43946153)
26. G.H.M. Kazatchkine, and U. Nydegger Techniques du complément 1986 INSERM Paris
27. C. Vauthier, B. Persson, P. Lindner, and B. Cabane Protein adsorption and complement activation for di-block copolymer nanoparticles Biomaterials 32 2011 1646 1656
28. D. Hanahan Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes Nature 315 1985 115 122 (Pubitemid 15064530)
29. E. Giraudo, M. Inoue, and D. Hanahan An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J. Clin. Invest. 114 2004 623 633 (Pubitemid 39578752)
30. M. Zerlin, M.A. Julius, and J. Kitajewski Wnt/Frizzled signaling in angiogenesis Angiogenesis 11 2008 63 69
31. A.T. Weeraratna, Y. Jiang, G. Hostetter, K. Rosenblatt, P. Duray, M. Bittner, and J.M. Trent Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma Cancer Cell 1 2002 279 288 (Pubitemid 41039152)
32. D. Wawrzak, M. Metioui, E. Willems, M. Hendrickx, E. de Genst, and L. Leyns Wnt3a binds to several sFRPs in the nanomolar range Biochem. Biophys. Res. Commun. 357 2007 1119 1123 (Pubitemid 46693687)
33. S.W. Reulen, P.Y. Dankers, P.H. Bomans, E.W. Meijer, and M. Merkx Collagen targeting using protein-functionalized micelles: the strength of multiple weak interactions J. Am. Chem. Soc. 131 2009 7304 7312
34. X. Montet, M. Funovics, K. Montet-Abou, R. Weissleder, and L. Josephson Multivalent effects of RGD peptides obtained by nanoparticle display J. Med. Chem. 49 2006 6087 6093 (Pubitemid 44484952)
35. J.D. Holland, A. Klaus, A.N. Garratt, and W. Birchmeier Wnt signaling in stem and cancer stem cells Curr. Opin. Cell Biol. 25 2013 254 264
36. S. Schinner, H.S. Willenberg, M. Schott, and W.A. Scherbaum Pathophysiological aspects of Wnt-signaling in endocrine disease Eur. J. Endocrinol. 160 2009 731 737
37. S. Yachida, S. Jones, I. Bozic, T. Antal, R. Leary, B.J. Fu, M. Kamiyama, R.H. Hruban, J.R. Eshleman, M.A. Nowak, V.E. Velculescu, K.W. Kinzler, B. Vogelstein, and C.A. Iacobuzio-Donahue Distant metastasis occurs late during the genetic evolution of pancreatic cancer Nature 467 2010 1114 1117
38. P.J. Campbell, S. Yachida, L.J. Mudie, P.J. Stephens, E.D. Pleasance, L.A. Stebbings, L.A. Morsberger, C. Latimer, S. McLaren, M.L. Lin, D.J. McBride, I. Varela, S.A. Nik-Zainal, C. Leroy, M.M. Jia, A. Menzies, A.P. Butler, J.W. Teague, C.A. Griffin, J. Burton, H. Swerdlow, M.A. Quail, M.R. Stratton, C. Iacobuzio-Donahue, and P.A. Futreal The patterns and dynamics of genomic instability in metastatic pancreatic cancer Nature 467 2010 1109 1113
39. S. Jones, X. Zhang, D.W. Parsons, J.C. Lin, R.J. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, S.M. Hong, B. Fu, M.T. Lin, E.S. Calhoun, M. Kamiyama, K. Walter, T. Nikolskaya, Y. Nikolsky, J. Hartigan, D.R. Smith, M. Hidalgo, S.D. Leach, A.P. Klein, E.M. Jaffee, M. Goggins, A. Maitra, C. Iacobuzio-Donahue, J.R. Eshleman, S.E. Kern, R.H. Hruban, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V.E. Velculescu, and K.W. Kinzler Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 2008 1801 1806
40. V. Corbo, G. Tortora, and A. Scarpa Molecular pathology of pancreatic cancer: from bench-to-bedside translation Curr. Drug Targets 13 2012 744 752
41. J.P. Morris, S.C. Wang, and M. Hebrok KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma Nat. Rev. Cancer 10 2010 683 695
42. M. Katoh WNT2 and human gastrointestinal cancer (review) Int. J. Mol. Med. 12 2003 811 816
43. A.E. Nel, L. Madler, D. Velegol, T. Xia, E.M. Hoek, P. Somasundaran, F. Klaessig, V. Castranova, and M. Thompson Understanding biophysicochemical interactions at the nano-bio interface Nat. Mater. 8 2009 543 557
44. S.M. Moghimi, A.J. Andersen, S.H. Hashemi, B. Lettiero, D. Ahmadvand, A.C. Hunter, T.L. Andresen, I. Hamad, and J. Szebeni Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead J. Control. Release 146 2010 175 181
45. S.M. Moghimi, and Z.S. Farhangrazi Nanomedicine and the complement paradigm Nanomedicine 9 2013 458 460
46. M.P. Carreno, F. Maillet, D. Labarre, M. Jozefowicz, and M.D. Kazatchkine Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum Biomaterials 9 1988 514 518 (Pubitemid 19001131)
47. C. Zandanel, and C. Vauthier Poly(isobutylcyanoacrylate) nanoparticles decorated with chitosan: effect of conformation of chitosan chains at the surface on complement activation properties J. Colloid Sci. Biotechnol. 1 2012 68 81
48. G. Bergers, K. Javaherian, K.M. Lo, J. Folkman, and D. Hanahan Effects of angiogenesis inhibitors on multistage carcinogenesis in mice Science 284 1999 808 812 (Pubitemid 29291347)
49. B.A. Teicher Tumor models for efficacy determination Mol. Cancer Ther. 5 2006 2435 2443 (Pubitemid 44650906)
50. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J. Clin. Invest. 111 2003 1287 1295 (Pubitemid 36554699)
51. F. Maione, F. Molla, C. Meda, R. Latini, L. Zentilin, M. Giacca, G. Seano, G. Serini, F. Bussolino, and E. Giraudo Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models J. Clin. Invest. 119 2009 3356 3372
52. F. Maione, S. Capano, D. Regano, L. Zentilin, M. Giacca, O. Casanovas, F. Bussolino, G. Serini, and E. Giraudo Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice J. Clin. Invest. 122 2012 1832 1848
53. L.H. Reddy, C. Dubernet, S.L. Mouelhi, P.E. Marque, D. Desmaele, and P. Couvreur A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types J. Control. Release 124 2007 20 27 (Pubitemid 350103730)
54. L.H. Reddy, J.M. Renoir, V. Marsaud, S. Lepetre-Mouelhi, D. Desmaele, and P. Couvreur Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor Mol. Pharm. 6 2009 1526 1535
55. S. Rejiba, L.H. Reddy, C. Bigand, C. Parmentier, P. Couvreur, and A. Hajri Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer Nanomedicine 7 2011 841 849
56. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62 (Pubitemid 40093472)